| Symbol | ABVX |
|---|---|
| Name | ABIVAX S.A. |
| Sector | UNDEFINED |
| Region | UNDEFINED |
| Industry | Pharmaceutical Preparations |
| Address | 7 BD HAUSSMANN, PARIS, None None |
| Telephone | 01 53 83 09 63 |
| Fax | — |
| — | |
| Website | — |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | None |
Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents
Read moreAbivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies
Read moreAbivax Announces Full Year 2025 Financial Results and Provides Business Updates
Read moreAbivax Announces Full Year 2025 Financial Results and Provides Business Updates
Read moreNew Form S-8 - Abivax S.A. <b>Filed:</b> 2026-03-23 <b>AccNo:</b> 0001193125-26-120026 <b>Size:</b> 262 KB
Read moreAbivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
Read moreNew Form SCHEDULE 13G/A - Abivax S.A. <b>Filed:</b> 2026-02-13 <b>AccNo:</b> 0002005369-26-000006 <b>Size:</b> 16 KB
Read more